Social determinants of health and variability in treatment for patients with early-stage non-small cell lung cancer
When using precise estimates of geospatial SDOH, these measures were associated with treatment and should be considered in analyses of cancer outcomes.
Authors
- Henry G. Kaplan (ORCID: https://orcid.org/0000-0001-9866-5200)
- Mark S. Wicks
- Molly Scannell Bryan (ORCID: https://orcid.org/0000-0003-1030-3155)
- Xiaohan Hu (ORCID: https://orcid.org/0000-0002-5608-2864)
- Monika A. Izano (ORCID: https://orcid.org/0000-0003-1852-5342)
- Hina Mohammed (ORCID: https://orcid.org/0000-0002-6600-961X)
- Anna B. Berry (ORCID: https://orcid.org/0000-0002-9246-4560)
- George R. Simon (ORCID: https://orcid.org/0000-0002-3894-0773)
- Thomas D. Brown (ORCID: https://orcid.org/0000-0002-2123-1014)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Moffitt Cancer Center (US)
- Chester County Historical Society (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1093/jncics/pkae117
- Citations
- 3
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 0.85